Standard differences in the major baseline covariates between the two treatment regimens.

<p>NYHA, New York Heart Association; PCI, percutaneous intervention; IABP, intra-aortic balloon pump; CPAP, continuous positive airway pressure; HR, heart rate; BNP, B-type natriuretic peptide; ACS, acute coronary syndrome; CAD, coronary artery disease; CHF, chronic heart failure; ACEI/ARB, angiotensin-converting-enzyme inhibitors/angiotensin II receptor blockers; BB, beta blockers; SBP, systolic blood pressure; LVEF, left ventricular ejection fraction.</p

Subgroup PS-weighted analyses of the <i>inopressors and inodilators</i> vs. <i>inopressors alone</i> on short-term mortality.

<p>HR, hazard ratios; PS, propensity score; SBP, systolic blood pressure; ACS, acute coronary syndrome.</p

Kaplan-Meier representation of mortality: A.

<p>As evaluated in the original pooled datasets; <b>B.</b> as evaluated in the pooled datasets after PS weighting. (Combined regimen stands for <i>inopressors and inodilators</i>).</p

Flowchart.

<p>Combined regimen stands for <i>inopressors and inodilators</i>; *patients excluded for missing data concerning the treatment regimen, the outcome or the length of hospital stay; ^$patients included in the final analysis.</p

Patients’ characteristics and differences between the two treatment groups.

<p>NYHA, New York Heart Association; ACS, acute coronary syndrome; CAD, coronary artery disease; CHF, chronic heart failure; BNP, B-type natriuretic peptide; renal disease, history of chronic renal failure; CPAP, continuous positive airway pressure; PCI, percutaneous coronary intervention ACEI/ARB, angiotensin-converting-enzyme inhibitors/angiotensin II receptor blockers. The systolic blood pressure (SBP), the heart rate (HR), the BNP, the serum creatinine and the left ventricular ejection fraction (LVEF) are presented as the median [IQR]. For categorical variables, the sum of the different categories might be inferior to the sample size because patients’ characteristics were analyzed from complete cases. The p values refer to the comparison of <i>inopressors alone</i> vs. <i>inopressors and inodilators</i>.</p

Patients’ characteristics and differences between the two treatment groups after PS weighting.

<p>NYHA, New York Heart Association; ACS, acute coronary syndrome; CAD, coronary artery disease; CHF, chronic heart failure; BNP, B-type natriuretic peptide; renal disease, history of chronic renal failure; CPAP, continuous positive airway pressure; PCI, percutaneous coronary intervention ACEI/ARB, angiotensin-converting-enzyme inhibitors/angiotensin II receptor blockers. The systolic blood pressure (SBP), the heart rate (HR), the BNP, the serum creatinine and the left ventricular ejection fraction (LVEF) are presented as the median [IQR]. For categorical variables, the sum of the different categories might be inferior to the sample size because patients’ characteristics were analyzed from complete cases. The p values refer to the comparison of <i>inopressors alone</i> vs. <i>inopressors and inodilators</i>.</p

Prevalence of depression and anxiety symptoms in the course of 1 year after PCI.

<p>Prevalence of depression and anxiety symptoms in the course of 1 year after PCI.</p

Loss of interest in sex in the course of 1 year after PCI.

<p>Loss of interest in sex in the course of 1 year after PCI.</p

Occurrence of positivity of questionnaire SAS.

<p>Occurrence of positivity of questionnaire SAS.</p

Additional file 1 of Statistical analysis plan for a randomized controlled trial examining pedometer-based walking intervention in patients with heart failure with reduced ejection fraction: the WATCHFUL trial

Additional file 1. Statistical Analysis Plan Checklist